Please login to the form below

Not currently logged in
Email:
Password:

Genzyme

This page shows the latest Genzyme news and features for those working in and with pharma, biotech and healthcare.

Dupixent helps put Sanofi back on growth track

Dupixent helps put Sanofi back on growth track

Gains for vaccine division Sanofi Pasteur and the company’s specialty medicines division, which along with Dupixent includes Genzyme’s rare disease drugs and multiple sclerosis therapies like Aubagio (teriflunomide), contributed ... Buoyed by an 8%

Latest news

More from news
Approximately 27 fully matching, plus 150 partially matching documents found.

Latest Intelligence

  • Trust me, I’m from pharma Trust me, I’m from pharma

    Rather than assuming anything, Sanofi Genzyme took a step back and asked patients: how can we help? ... In Sanofi Genzyme’s case, it culminated in a set of briefs that were owned by the patients living with the disease.

  • Pharma deals in July 2015 Pharma deals in July 2015

    Firstly the divestment for up to $300m to Genzyme of Caprelsa (vandetanib), an orphan drug treatment for thyroid carcinoma. ... 560+. AstraZeneca / Genzyme. Acquisition of R&D. Caprelsa (vandetanib) marketed. 300.

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Voyager Therapeutics/ Sanofi (Genzyme). Gene therapy - Parkinson's disease, Friedreich's ataxia and Huntington's disease.

  • Pharma deals during November 2014 Pharma deals during November 2014

    Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme and approved by the FDA in August this year.

  • Pharma deals during January 2014 Pharma deals during January 2014

    The now expanded deal grants Genzyme rights in all markets outside North America and Western Europe. ... In 2008 Genzyme gained rights to ataluren from PTC Therapeutics at a cost of $100m.

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

More from appointments
Approximately 4 fully matching, plus 35 partially matching documents found.

Latest from PMHub

  • Lucid Group make the cut at the PMEAs 2017

    OptiMiSe: a Multichannel Learning Platform for Clinical Behaviour Change Among Multiple Sclerosis Specialist Nurses, by Sanofi Genzyme, with support from Lucid Group.

  • Lucid celebrate big wins at PMEA 2015

    Success for Lucid at PMEA 2015. Lucid group successfully supported AbbVie and Genzyme to win two awards at last night’s ceremony in London. ... And they celebrated with Genzyme after supporting them to win the award for launch excellence.

  • Lucid Group Communications Limited

    Celgene. CSL Behring. Eisai. Ferring Pharmaceuticals Ltd. Genzyme. Gilead. GlaxoSmithKline. Janssen.

  • HAVAS LYNX

    AbbVie. Alexion. Almirall. Astellas. AstraZeneca. Bayer. Eisai. Genzyme. Janssen. Kowa. Lilly.

  • Swordfish Advertising

    At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat and tears. The best campaigns always do. But we take a lot of pride in translating that behind-the-scenes effort into

More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics